Myelodysplastic Syndromes
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndromes.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) [Phase 1]
Phase 1 study of JNJ-74856665 in participants with Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Chronic Myelomonocytic Leukemia has…
-
CLINICAL_TRIALS trial_result · 2025-09-30Clinical Trial Update: ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML) [Phase 2]
Phase 2 trial ACHIEVE evaluating adoptive cellular therapy with ex-vivo expanded allogeneic γδ T-lymphocytes (TCB008) for refractory or rela…
-
CLINICAL_TRIALS trial_result · 2025-09-30Clinical Trial Update: Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome. [Phase 3]
This document provides a status update on a Phase 3 clinical trial evaluating the effectiveness and safety of Luspatercept in patients with …
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies [EARLY_Phase 1]
An early-phase trial evaluating Darzalex Faspro (daratumumab and hyaluronidase-fihj) given before desensitization and allogeneic stem cell t…
-
CLINICAL_TRIALS trial_result · 2025-09-25Clinical Trial Update: A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes [Phase 1]
This Phase 1 trial update reports results for CC-95251 in acute myeloid leukemia and myelodysplastic syndromes. The study has been terminate…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-09-25Clinical Trial Update: Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study
The CREST study update shows the cardiovascular reserve evaluation trial in transplant survivors is currently active but not recruiting, spo…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes [Phase 2]
A Phase 2 clinical trial update for SP-420 in transfusion-dependent beta-thalassemia and low-risk myelodysplastic syndromes, currently recru…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome [Phase 1]
Phase 1 clinical trial evaluating BH-30236 in patients with relapsed or refractory acute myeloid leukemia and higher-risk myelodysplastic sy…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: NTX-301 in MDS/AML [Phase 1]
Phase 1 clinical trial update for NTX-301 in acute myeloid leukemia and myelodysplastic syndromes, including chronic myelomonocytic leukemia…
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 1]
Phase 1 study of SGR-2921 in relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes has been terminated.
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study) [NA]
A clinical trial evaluating the addition of venetoclax to busulfan/cyclophosphamide conditioning for high-risk acute myeloid leukemia and my…
-
CLINICAL_TRIALS research · 2025-09-18Clinical Trial Update: Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients [Phase 1]
Phase 1 trial evaluating Itacitinib with high-dose posttransplantation cyclophosphamide in older patients. The study is currently ACTIVE_NOT…
-
CLINICAL_TRIALS research · 2025-09-18Clinical Trial Update: BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS [Phase 1, Phase 2]
Update on a Phase 1/2 trial of BSB-1001 in patients undergoing HLA-matched allogeneic hematopoietic stem cell transplantation for acute myel…
-
CLINICAL_TRIALS research · 2025-09-17Clinical Trial Update: HEME Home Transfusion Program [NA]
Clinical trial update indicates that the HEME Home Transfusion Program is currently recruiting for hematologic conditions including leukemia…
-
CLINICAL_TRIALS research · 2025-09-17Clinical Trial Update: Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
An ongoing University of Rochester clinical trial investigates monitoring minimal residual disease in patients with acute myeloid leukemia o…
-
CLINICAL_TRIALS research · 2025-09-16Clinical Trial Update: TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCT [Phase 1]
A Phase 1 trial evaluating total body irradiation delivered with IMRT (VMAT or Tomotherapy) to prevent pulmonary toxicities in patients unde…
-
CLINICAL_TRIALS research · 2025-09-12Clinical Trial Update: Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients [Phase 2]
This Phase 2 clinical trial is investigating whether immediate allogeneic hematopoietic stem cell transplantation is more effective than a b…
-
EMA approval · 2025-09-09EMA Authorised: Revlimid (lenalidomide) — Bristol-Myers Squibb Pharma EEIG
The European Medicines Agency authorised Revlimid (lenalidomide) for multiple indications including multiple myeloma, mantle cell lymphoma, …
-
FDA approval · 2025-09-08FDA Approved: DEFERASIROX — Original Application (Aurobindo Pharma Limited)
The FDA approved an original ANDA for deferasirox (generic) manufactured by Aurobindo Pharma Limited, expanding access to iron chelation the…
-
CLINICAL_TRIALS research · 2025-09-08Clinical Trial Update: Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes [NA]
This is a completed prospective study evaluating molecular predictors of survival in patients with myelodysplastic syndromes.
-
CLINICAL_TRIALS research · 2025-09-04Clinical Trial Update: A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant [Phase 2]
The update describes a Phase 2 study of a modified dose of rabbit anti-thymocyte globulin (rATG) used to condition patients (children and ad…
-
CLINICAL_TRIALS research · 2025-09-02Clinical Trial Update: Establishment of a Strategy for Preventing Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation by Exploring Immune Mechanisms of Regulatory and Effector T Cells
This clinical trial update outlines an approach to prevent graft-versus-host disease after allogeneic hematopoietic cell transplantation by …
-
CLINICAL_TRIALS trial_result · 2025-08-27Clinical Trial Update: Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes [Phase 1]
Phase 1 study evaluating safety and tolerability of CC-91633 (BMS-986397) in participants with relapsed or refractory acute myeloid leukemia…
-
CLINICAL_TRIALS trial_result · 2025-08-26Clinical Trial Update: Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia [Phase 2]
This Phase 2 trial examines hematopoietic stem cell transplantation for infant leukemia and has completed with results posted.
-
CLINICAL_TRIALS research · 2025-08-26Clinical Trial Update: Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML [Phase 2]
Phase 2 clinical trial evaluating a metabolically optimized, non-cytotoxic, low-dose weekly decitabine/venetoclax regimen in myelodysplastic…